Family history and APOE-4 genetic risk in Alzheimer's disease

Neuropsychology Review

Volumn 22, Issue 3, 2012, Pages 298-309

  Donix, Markus ^a,b   Small, Gary W ^c,e   Bookheimer, Susan Y ^c,d  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; APOE genotype; Family history; Genetic risk; Neuroimaging; Risk factors

Indexed keywords

APOLIPOPROTEIN E4; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; BRAIN; CEREBROSPINAL FLUID; DIFFUSION TENSOR IMAGING; FAMILY; FUNCTIONAL NEUROIMAGING; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW; RISK FACTOR;

ALZHEIMER DISEASE; APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; BRAIN; DIFFUSION TENSOR IMAGING; FAMILY; FUNCTIONAL NEUROIMAGING; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROIMAGING; PHENOTYPE; POSITRON-EMISSION TOMOGRAPHY; RISK FACTORS;

EID: 84866945232     PISSN: 10407308     EISSN: 15736660     Source Type: Journal    
DOI: 10.1007/s11065-012-9193-2     Document Type: Review

References (98)

1. Anand, S. S., Xie, C., Pare, G., Montpetit, A., Rangarajan, S., McQueen, M. J., et al. (2009). Genetic variants associated with myocardial infarction risk factors in over 8000 individuals from five ethnic groups: The INTERHEART Genetics Study. Circulation. Cardiovascular Genetics, 2(1), 16-25.
2. Bandettini, P. A., & Ungerleider, L. G. (2001). From neuron to BOLD: new connections. Nature Neuroscience, 4(9), 864-866.
3. Bassett, S. S., Yousem, D. M., Cristinzio, C., Kusevic, I., Yassa, M. A., Caffo, B. S., et al. (2006). Familial risk for Alzheimer's disease alters fMRI activation patterns. Brain, 129(Pt 5), 1229-1239.
4. Bendlin, B. B., Ries, M. L., Canu, E., Sodhi, A., Lazar, M., Alexander, A. L., et al. (2010). White matter is altered with parental family history of Alzheimer's disease. Alzheimer's & Dementia, 6(5), 394-403.
5. Blazquez, L., Otaegui, D., Saenz, A., Paisan-Ruiz, C., Emparanza, J. I., Ruiz-Martinez, J., et al. (2006). Apolipoprotein E epsilon4 allele in familial and sporadic Parkinson's disease. Neuroscience Letters, 406(3), 235-239.
6. Bondi, M. W., Houston, W. S., Eyler, L. T., & Brown, G. G. (2005). fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. Neurology, 64(3), 501-508.
7. Bookheimer, S. Y., Strojwas, M. H., Cohen, M. S., Saunders, A. M., Pericak-Vance, M. A., Mazziotta, J. C., et al. (2000). Patterns of brain activation in people at risk for Alzheimer's disease. The New England Journal of Medicine, 343(7), 450-456.
8. Borenstein, A. R., Copenhaver, C. I., & Mortimer, J. A. (2006). Earlylife risk factors for Alzheimer disease. Alzheimer Disease and Associated Disorders, 20(1), 63-72.
9. Braak, H., & Braak, E. (1997). Staging of Alzheimer-related cortical destruction. International Psychogeriatrics, 9(Suppl 1), 257-261. discussion 269-272.
10. Bretsky, P., Guralnik, J. M., Launer, L., Albert, M., & Seeman, T. E. (2003). The role of APOE-epsilon4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging. Neurology, 60(7), 1077-1081.
11. Brown, J. A., Terashima, K. H., Burggren, A. C., Ercoli, L. M., Miller, K. J., Small, G. W., et al. (2011). Brain network local interconnectivity loss in aging APOE-4 allele carriers. Proceedings of the National Academy of Sciences USA [in press]
12. Bunce, D., Fratiglioni, L., Small, B. J., Winblad, B., & Backman, L. (2004). APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging. Neurology, 63(5), 816-821.
13. Burggren, A. C., Zeineh, M. M., Ekstrom, A. D., Braskie, M. N., Thompson, P. M., Small, G. W., et al. (2008). Reduced cortical thickness in hippocampal subregions among cognitively normal apolipoprotein E e4 carriers. NeuroImage, 41(4), 1177-1183.
14. Caselli, R. J., Reiman, E. M., Locke, D. E., Hutton, M. L., Hentz, J. G., Hoffman-Snyder, C., et al. (2007). Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. Archives of Neurology, 64(9), 1306-1311.
15. Caselli, R. J., Dueck, A. C., Locke, D. E., Sabbagh, M. N., Ahern, G. L., Rapcsak, S. Z., et al. (2011). Cerebrovascular risk factors and preclinical memory decline in healthy APOE epsilon4 homozygotes. Neurology, 76(12), 1078-1084.
16. Chapman, J., Korczyn, A. D., Karussis, D. M., & Michaelson, D. M. (2001). The effects of APOE genotype on age at onset and progression of neurodegenerative diseases. Neurology, 57(8), 1482-1485.
17. Chen, K., Reiman, E. M., Alexander, G. E., Caselli, R. J., Gerkin, R., Bandy, D., et al. (2007). Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates. The American Journal of Psychiatry, 164(6), 916-921.
18. *E4 status in a community sample of middleaged individuals. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 63(5), 501-504.
19. Cupples, L. A., Farrer, L. A., Sadovnick, A. D., Relkin, N., Whitehouse, P., & Green, R. C. (2004). Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genetics in Medicine, 6(4), 192-196.
20. Daw, E. W., Payami, H., Nemens, E. J., Nochlin, D., Bird, T. D., Schellenberg, G. D., et al. (2000). The number of trait loci in late-onset Alzheimer disease. American Journal of Human Genetics, 66(1), 196-204.
21. Donix, M., Burggren, A., Suthana, N., Siddarth, P., Ekstrom, A., Krupa, A., et al. (2010a). Family history of Alzheimer's disease and hippocampal structure in healthy people. The American Journal of Psychiatry, 167(11), 1399-1406.
22. Donix, M., Burggren, A. C., Suthana, N. A., Siddarth, P., Ekstrom, A. D., Krupa, A. K., et al. (2010b). Longitudinal changes in medial temporal cortical thickness in normal subjects with the APOE-4 polymorphism. NeuroImage, 53, 37-43.
23. Donix, M., Ercoli, L. M., Siddarth, P., Brown, J. A., Martin-Harris, L., Burggren, A. C., et al. (2011). Influence of Alzheimer disease family history and genetic risk on cognitive performance in healthy middle-aged and older people. American Journal of Geriatric Psychiatry [in press]
24. Dubois, B., Feldman, H. H., Jacova, C., Dekosky, S. T., Barberger-Gateau, P., Cummings, J., et al. (2007). Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurology, 6(8), 734-746.
25. During, E. H., Osorio, R. S., Elahi, F. M., Mosconi, L., & De Leon, M. J. (2011). The concept of FDG-PET endophenotype in Alzheimer's disease. Neurological Science, 32(4), 559-569.
26. Ekstrom, A. (2010). How and when the fMRI BOLD signal relates to underlying neural activity: the danger in dissociation. Brain Research Reviews, 62(2), 233-244.
27. Elosua, R., Ordovas, J. M., Cupples, L. A., Fox, C. S., Polak, J. F., Wolf, P. A., et al. (2004). Association of APOE genotype with carotid atherosclerosis in men and women: the Framingham Heart Study. Journal of Lipid Research, 45(10), 1868-1875.
28. Espeseth, T., Westlye, L. T., Fjell, A. M., Walhovd, K. B., Rootwelt, H., & Reinvang, I. (2008). Accelerated age-related cortical thinning in healthy carriers of apolipoprotein E epsilon 4. Neurobiology of Aging, 29(3), 329-340.
29. Filbey, F. M., Slack, K. J., Sunderland, T. P., & Cohen, R. M. (2006). Functional magnetic resonance imaging and magnetoencephalography differences associated with APOEepsilon4 in young healthy adults. Neuroreport, 17(15), 1585-1590.
30. Filippini, N., MacIntosh, B. J., Hough, M. G., Goodwin, G. M., Frisoni, G. B., Smith, S. M., et al. (2009). Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proceedings of the National Academy of Sciences of the United States of America, 106(17), 7209-7214.
31. Filippini, N., Ebmeier, K. P., MacIntosh, B. J., Trachtenberg, A. J., Frisoni, G. B., Wilcock, G. K., et al. (2011). Differential effects of the APOE genotype on brain function across the lifespan. Neuro-Image, 54(1), 602-610.
32. Fleisher, A. S., Houston, W. S., Eyler, L. T., Frye, S., Jenkins, C., Thal, L. J., et al. (2005). Identification of Alzheimer disease risk by functional magnetic resonance imaging. Archives of Neurology, 62(12), 1881-1888.
33. Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). Mini-Mental-State: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189-198.
34. Fratiglioni, L., Ahlbom, A., Viitanen, M., & Winblad, B. (1993). Risk factors for late-onset Alzheimer's disease: a population-based, case-control study. Annals of Neurology, 33(3), 258-266.
35. Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., et al. (2006). Role of genes and environments for explaining Alzheimer disease. Archives of General Psychiatry, 63(2), 168-174.
36. Glodzik-Sobanska, L., Pirraglia, E., Brys, M., De Santi, S., Mosconi, L., Rich, K. E., et al. (2009). The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiology of Aging, 30(5), 672-681.
37. Gold, B. T., Powell, D. K., Andersen, A. H., & Smith, C. D. (2010). Alterations in multiple measures of white matter integrity in normal women at high risk for Alzheimer's disease. NeuroImage, 52(4), 1487-1494.
38. Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., et al. (2009). Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 41(10), 1088-1093.
39. Hayden, K. M., Zandi, P. P., West, N. A., Tschanz, J. T., Norton, M. C., Corcoran, C., et al. (2009). Effects of family history and apolipoprotein E epsilon4 status on cognitive decline in the absence of Alzheimer dementia: the Cache County Study. Archives of Neurology, 66(11), 1378-1383.
40. Hebert, L. E., Beckett, L. A., Scherr, P. A., & Evans, D. A. (2001). Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Disease and Associated Disorders, 15(4), 169-173.
41. Heise, V., Filippini, N., Ebmeier, K. P., & Mackay, C. E. (2011). The APOE varepsilon4 allele modulates brain white matter integrity in healthy adults. Molecular Psychiatry, 16(9), 908-916.
42. Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., et al. (2008). Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebocontrolled phase I trial. Lancet, 372(9634), 216-223.
43. Honea, R. A., Vidoni, E., Harsha, A., & Burns, J. M. (2009). Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study. Journal of Alzheimer's Disease, 18(3), 553-564.
44. Honea, R. A., Swerdlow, R. H., Vidoni, E. D., Goodwin, J., & Burns, J. M. (2010). Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease. Neurology, 74(2), 113-120.
45. Honea, R. A., Swerdlow, R. H., Vidoni, E. D., & Burns, J. M. (2011). Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease. Neurology, 76(9), 822-829.
46. Jak, A. J., Houston, W. S., Nagel, B. J., Corey-Bloom, J., & Bondi, M. W. (2007). Differential cross-sectional and longitudinal impact of APOE genotype on hippocampal volumes in nondemented older adults. Dementia and Geriatric Cognitive Disorders, 23(6), 382-389.
47. Jarvik, G. P., & Wijsman, E. M. (1994). Alzheimer's disease and the family effect. Nature Genetics, 8(2), 115.
48. Johnson, S. C., Schmitz, T. W., Trivedi, M. A., Ries, M. L., Torgerson, B. M., Carlsson, C. M., et al. (2006). The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation. Journal of Neuroscience, 26(22), 6069-6076.
49. Lambert, J. C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., et al. (2009). Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genetics, 41(10), 1094-1099.
50. Langbaum, J. B., Chen, K., Launer, L. J., Fleisher, A. S., Lee, W., Liu, X., et al. (2011). Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. Neurobiology of Aging [in press]
51. La Rue, A., Hermann, B., Jones, J. E., Johnson, S., Asthana, S., & Sager, M. A. (2008). Effect of parental family history of Alzheimer's disease on serial position profiles. Alzheimer's & Dementia, 4(4), 285-290.
52. Lin, M. T., & Beal, M. F. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 443(7113), 787-795.
53. Lind, J., Persson, J., Ingvar, M., Larsson, A., Cruts, M., Van Broeckhoven, C., et al. (2006). Reduced functional brain activity response in cognitively intact apolipoprotein E epsilon4 carriers. Brain, 129(Pt 5), 1240-1248.
54. Logothetis, N. K., Pauls, J., Augath, M., Trinath, T., & Oeltermann, A. (2001). Neurophysiological investigation of the basis of the fMRI signal. Nature, 412(6843), 150-157.
55. Luchsinger, J. A. (2008). Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective. European Journal of Pharmacology, 585(1), 119-129.
56. Lunetta, K. L., Erlich, P. M., Cuenco, K. T., Cupples, L. A., Green, R. C., Farrer, L. A., et al. (2007). Heritability of magnetic resonance imaging (MRI) traits in Alzheimer disease cases and their siblings in the MIRAGE study. Alzheimer Disease and Associated Disorders, 21(2), 85-91.
57. Mahley, R. W., Weisgraber, K. H., & Huang, Y. (2006). Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 103(15), 5644-5651.
58. Mastroeni, D., Grover, A., Delvaux, E., Whiteside, C., Coleman, P. D., & Rogers, J. (2011). Epigenetic mechanisms in Alzheimer's disease. Neurobiology of Aging, 32(7), 1161-1180.
59. Mielke, M. M., Leoutsakos, J. M., Tschanz, J. T., Green, R. C., Tripodis, Y., Corcoran, C. D., et al. (2011). Interaction between vascular factors and the APOE epsilon4 allele in predicting rate of progression in Alzheimer's disease. Journal of Alzheimer's Disease, 26(1), 127-134.
60. Mosconi, L., Brys, M., Switalski, R., Mistur, R., Glodzik, L., Pirraglia, E., et al. (2007). Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proceedings of the National Academy of Sciences of the United States of America, 104(48), 19067-19072.
61. Mosconi, L., Mistur, R., Switalski, R., Brys, M., Glodzik, L., Rich, K., et al. (2009). Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology, 72(6), 513-520.
62. Mosconi, L., Glodzik, L., Mistur, R., McHugh, P., Rich, K. E., Javier, E., et al. (2010). Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer's. Biological Psychiatry, 68(10), 913-921.
63. Mosconi, L., Rinne, J. O., Tsui, W. H., Berti, V., Li, Y., Wang, H., et al. (2010). Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proceedings of the National Academy of Sciences of the United States of America, 107(13), 5949-5954.
64. Mosconi, L., Tsui, W., Murray, J., McHugh, P., Li, Y., Williams, S., et al. (2011). Maternal age affects brain metabolism in adult children of mothers affected by Alzheimer's disease. Neurobiology of Aging [in press]
65. Mount, C., & Downton, C. (2006). Alzheimer disease: progress or profit? Nature Medicine, 12(7), 780-784.
66. Mueller, S. G., Schuff, N., Raptentsetsang, S., Elman, J., & Weiner, M. W. (2008). Selective effect of Apo e4 on CA3 and dentate in normal aging and Alzheimer's disease using high resolution MRI at 4T. NeuroImage, 42(1), 42-48.
67. Murrell, J., Ghetti, B., Cochran, E., Macias-Islas, M. A., Medina, L., Varpetian, A., et al. (2006). The A431E mutation in PSEN1 causing familial Alzheimer's disease originating in Jalisco State, Mexico: an additional fifteen families. Neurogenetics, 7(4), 277-279.
68. Nierenberg, J., Pomara, N., Hoptman, M. J., Sidtis, J. J., Ardekani, B. A., & Lim, K. O. (2005). Abnormal white matter integrity in healthy apolipoprotein E epsilon4 carriers. Neuroreport, 16(12), 1369-1372.
69. Ohm, T. G., Muller, H., Braak, H., & Bohl, J. (1995). Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer's disease-related neurofibrillary changes. Neuroscience, 64(1), 209-217.
70. Persson, J., Lind, J., Larsson, A., Ingvar, M., Cruts, M., Van Broeckhoven, C., et al. (2006). Altered brain white matter integrity in healthy carriers of the APOE epsilon4 allele: a risk for AD? Neurology, 66(7), 1029-1033.
71. Popp, J., Lewczuk, P., Frommann, I., Kolsch, H., Kornhuber, J., Maier, W., et al. (2010). Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEepsilon4 genotype. Journal of Alzheimer's Disease, 22(2), 459-468.
72. Reiman, E. M., Caselli, R. J., Chen, K., Alexander, G. E., Bandy, D., & Frost, J. (2001). Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 98(6), 3334-3339.
73. Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., et al. (2004). Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proceedings of the National Academy of Sciences of the United States of America, 101(1), 284-289.
74. Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., et al. (2005). Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proceedings of the National Academy of Sciences of the United States of America, 102(23), 8299-8302.
75. Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., et al. (2009). Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 106(16), 6820-6825.
76. Ringman, J. M., Medina, L. D., Braskie, M., Rodriguez-Agudelo, Y., Geschwind, D. H., Macias-Islas, M. A., et al. (2011). Effects of risk genes on BOLD activation in presymptomatic carriers of familial Alzheimer's disease mutations during a novelty encoding task. Cerebral Cortex, 21(4), 877-883.
77. Robinson, G. E., Fernald, R. D., & Clayton, D. F. (2008). Genes and social behavior. Science, 322(5903), 896-900.
78. Ryan, L., Walther, K., Bendlin, B. B., Lue, L. F., Walker, D. G., & Glisky, E. L. (2011). Age-related differences in white matter integrity and cognitive function are related to APOE status. NeuroImage, 54(2), 1565-1577.
79. Saunders, A. M. (2000). Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses. Journal of Neuropathology and Experimental Neurology, 59(9), 751-758.
80. Seshadri, S., Fitzpatrick, A. L., Ikram, M. A., De Stefano, A. L., Gudnason, V., Boada, M., et al. (2010). Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA: The Journal of the American Medical Association, 303(18), 1832-1840.
81. Shaw, P., Lerch, J. P., Pruessner, J. C., Taylor, K. N., Rose, A. B., Greenstein, D., et al. (2007). Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study. Lancet Neurology, 6(6), 494-500.
82. Small, B. J., Rosnick, C. B., Fratiglioni, L., & Backman, L. (2004). Apolipoprotein E and cognitive performance: a meta-analysis. Psychology and Aging, 19(4), 592-600.
83. Small, G. W., Siddarth, P., Burggren, A. C., Kepe, V., Ercoli, L. M., Miller, K. J., et al. (2009). Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. Archives of General Psychiatry, 66(1), 81-87.
84. Smith, C. D., Chebrolu, H., Andersen, A. H., Powell, D. A., Lovell, M. A., Xiong, S., et al. (2010). White matter diffusion alterations in normal women at risk of Alzheimer's disease. Neurobiology of Aging, 31(7), 1122-1131.
85. Sunderland, T., Mirza, N., Putnam, K. T., Linker, G., Bhupali, D., Durham, R., et al. (2004). Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biological Psychiatry, 56(9), 670-676.
86. Teter, B. (2004). ApoE-dependent plasticity in Alzheimer's disease. Journal of Molecular Neuroscience, 23(3), 167-179.
87. Trivedi, M. A., Schmitz, T. W., Ries, M. L., Torgerson, B. M., Sager, M. A., Hermann, B. P., et al. (2006). Reduced hippocampal activation during episodic encoding in middle-aged individuals at genetic risk of Alzheimer's disease: a cross-sectional study. BMC Medicine, 4, 1-14.
88. Trivedi, M. A., Schmitz, T. W., Ries, M. L., Hess, T. M., Fitzgerald, M. E., Atwood, C. S., et al. (2008). fMRI activation during episodic encoding and metacognitive appraisal across the lifespan: risk factors for Alzheimer's disease. Neuropsychologia, 46(6), 1667-1678.
89. Tuminello, E. R., & Han, S. D. (2011). The apolipoprotein e antagonistic pleiotropy hypothesis: review and recommendations. Int J Alzheimers Dis, 2011, 726197.
90. Van Duijn, C. M., Clayton, D., Chandra, V., Fratiglioni, L., Graves, A. B., Heyman, A., et al. (1991). Familial aggregation of Alzheimer's disease and related disorders: a collaborative re-analysis of casecontrol studies. International Journal of Epidemiology, 20(Suppl 2), S13-S20.
91. Van Duijn, C. M., De Knijff, P., Cruts, M., Wehnert, A., Havekes, L. M., Hofman, A., et al. (1994). Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease. Nature Genetics, 7(1), 74-78.
92. Van Exel, E., Eikelenboom, P., Comijs, H., Frolich, M., Smit, J. H., Stek, M. L., et al. (2009). Vascular factors and markers of inflammation in offspring with a parental history of late-onset Alzheimer disease. Archives of General Psychiatry, 66(11), 1263-1270.
93. Wisdom, N. M., Callahan, J. L., & Hawkins, K. A. (2011). The effects of apolipoprotein E on non-impaired cognitive functioning: a meta-analysis. Neurobiology of Aging, 32(1), 63-74.
94. Wishart, H. A., Saykin, A. J., Rabin, L. A., Santulli, R. B., Flashman, L. A., Guerin, S. J., et al. (2006). Increased brain activation during working memory in cognitively intact adults with the APOE epsilon4 allele. The American Journal of Psychiatry, 163(9), 1603-1610.
95. Wisniewski, T., & Boutajangout, A. (2010). Vaccination as a therapeutic approach to Alzheimer's disease. The Mount Sinai Journal of Medicine, 77(1), 17-31.
96. Xu, G., McLaren, D. G., Ries, M. L., Fitzgerald, M. E., Bendlin, B. B., Rowley, H. A., et al. (2009). The influence of parental history of Alzheimer's disease and apolipoprotein E epsilon4 on the BOLD signal during recognition memory. Brain, 132(Pt 2), 383-391.
97. Yip, A. G., McKee, A. C., Green, R. C., Wells, J., Young, H., Cupples, L. A., et al. (2005). APOE, vascular pathology, and the AD brain. Neurology, 65(2), 259-265.
98. Zintl, M., Schmitz, G., Hajak, G., & Klunemann, H. H. (2009). ApoE genotype and family history in patients with dementia and cognitively intact spousal controls. American Journal of Alzheimer's Disease and Other Dementias, 24(4), 349-352.